Ono Pharmaceutical Co. Ltd: all 157 studies

Page 1 of 2. Open to participants first (25), then studies with results posted, then the rest; newest registration first within each.

• A Study of DCC-3014 to Evaluate the Efficacy, Safety, and Pharmacokinetics in Subjects With TGCTNot yet recruitingNCT07832747Phase 2
• A Trial of ONO-2808 in Participants With the Parkinsonian Subtype of Multiple System Atrophy (MSA-P)Not yet recruitingNCT07825402Phase 3
• ONO-4915 in Patients With Primary Sjogren's DiseaseNot yet recruitingNCT07823790Phase 2
• A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal AdenocarcinomaNot yet recruitingNCT07818070Phase 3
• A Study of ONO-7429 in Participants With Unresectable Advanced or Recurrent Solid TumorsRecruitingNCT07787208Phase 1
• A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ONO-6414 Administered Orally in Healthy Adult Participants and Patients With Active Ulcerative ColitisRecruitingNCT07749768Phase 1
• Evaluate the Effect of Vimseltinib on P-glycoprotein (P-gp) Inhibition in Healthy Male ParticipantsRecruitingNCT07744802Phase 1
• A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma.RecruitingNCT07734116Phase 1/2
• A Study of ONO-3310 in Healthy Adult Male Subjects and Chronic Kidney Disease Patients With Type 2 Diabetes MellitusRecruitingNCT07619157Phase 1
• Study of DCC-2618 in Patients With GIST After at Least 3 Prior TreatmentsRecruitingNCT07618377Phase 1
• A Study to Evaluate the Safety, Efficacy, and PK of ONO-2017 in Japanese Patients With POS 2 to 17 Year OldsRecruitingNCT07594158Phase 3
• INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)RecruitingNCT07429266Phase 3
• A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC Patients: Real-World Experience in Taiwan (NEOREAL)RecruitingNCT07169708
• IGNITE: Study of Tirabrutinib vs Rituximab and Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)RecruitingNCT07104032Phase 3
• MOVE: Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With VimseltinibRecruitingNCT07075471
• Study of DCC-2812 in Participants With Advanced Genitourinary CancersRecruitingNCT06966024Phase 1
• A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal CancerRecruitingNCT06948448Phase 2
• ONO-4538 Study in Patients With Richter's TransformationRecruitingNCT06936943Phase 2
• A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease DementiaRecruitingNCT06803823Phase 2
• A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)RecruitingNCT06630234Phase 1/2
• Study to ONO-4538 in Patients With Rhabdoid TumorRecruitingNCT06622941Phase 2
• A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)RecruitingNCT06619561Phase 2
• Safety of Cenobamate in Japanese Subjects With Partial Onset SeizuresRecruitingNCT06590896Phase 2
• ONO-2017 Study Japanese Patients With Primary Generalized Tonic Clonic Seizures.RecruitingNCT06579573Phase 3
• ONO-4538 Phase II Rollover Study (ONO-4538-98)RecruitingNCT04566380Phase 2
• A Phase 2 Study of ONO-2808 in Patients With Multiple System AtrophyActive, not recruitingNCT05923866Phase 2Results posted
• Study of Vimseltinib for Tenosynovial Giant Cell TumorActive, not recruitingNCT05059262Phase 3Results posted
• A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid TumorsTerminatedNCT03717415Phase 1/2Results posted
• A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With ImatinibActive, not recruitingNCT03673501Phase 3Results posted
• A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid TumorsTerminatedNCT03601897Phase 1/2Results posted
• Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer TherapiesCompletedNCT03353753Phase 3Results posted
• A Study of ONO-7475 in Patients With Acute LeukemiasTerminatedNCT03176277Phase 1/2Results posted
• Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)CompletedNCT03117049Phase 3Results posted
• Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal CancerCompletedNCT02569242Phase 3Results posted
• ONO-4538 Phase I Study in Patients With Solid TumorCompletedNCT02261285Phase 1Results posted
• ONO-4538 Study in Patients With Advanced Non-Small Cell Lung CancerCompletedNCT02175017Phase 2Results posted
• ONO-4538 Phase I Study in Patients With Advanced Malignant Solid Tumors in JapanCompletedNCT00836888Phase 1Results posted
• Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)CompletedNCT07539090Phase 1
• A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy ParticipantsCompletedNCT07198087Phase 1
• Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2)CompletedNCT07158411Phase 1
• Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 SubstrateCompletedNCT07158398Phase 1
• A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's DiseaseCompletedNCT06881836Phase 2
• A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid TumorsActive, not recruitingNCT06816108Phase 1
• A Study of ONO-1110 in Patients With Social Anxiety DisorderCompletedNCT06805565Phase 2
• A Study of ONO-1110 in Patients With Major Depressive DisorderCompletedNCT06792136Phase 2
• A Clinical Study of ONO-1110 in Patients With Hunner Type Interstitial CystitisCompletedNCT06752603Phase 2
• A Clinical Study of ONO-1110 in Patients With FibromyalgiaCompletedNCT06752590Phase 2
• Real-World Evidence of Effectiveness and Safety of Tirabrutinib in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: A Nationwide StudyCompletedNCT06714370
• A Study of ONO-1110 in Patients With Postherpetic NeuralgiaCompletedNCT06708416Phase 2
• ONO-4059 Study in Patients With Steroid-resistant PemphigusActive, not recruitingNCT06696716Phase 3
• A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin LymphomaTerminatedNCT06622226Phase 1
• ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast CancerCompletedNCT06570031Phase 1
• A Phase I Study of ONO-4538HSC in Subjects With Advanced or Metastatic Solid TumorsActive, not recruitingNCT06548217Phase 1
• A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLLActive, not recruitingNCT06547528Phase 1
• Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal CancerActive, not recruitingNCT06547385Phase 1
• An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung CancerCompletedNCT06542731Phase 1
• Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSLActive, not recruitingNCT06541665Phase 1
• The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal CancerActive, not recruitingNCT06540261Phase 1
• Study to Investigate the Chemotherapy-Induced Peripheral Neuropathy (CIPN) Onset-Suppressing Effect and Safety of ONO-2910 in Patients With Breast Cancer Receiving Weekly PaclitaxelCompletedNCT06538272Phase 2
• An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic CancerCompletedNCT06538207Phase 1
• Study of ONO-7914 Alone and in Combination With ONO-4538 in Patients With Solid TumorsTerminatedNCT06535009Phase 1
• An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic CancerActive, not recruitingNCT06532344Phase 1
• A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic CancerActive, not recruitingNCT06532331Phase 1
• Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung CancerCompletedNCT06525246Phase 1
• Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) PathwayTerminatedNCT06287463Phase 1
• A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)Active, not recruitingNCT06256328Phase 2
• A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced MalignanciesActive, not recruitingNCT05957367Phase 1/2
• A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With ImatinibActive, not recruitingNCT05734105Phase 3
• A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLLTerminatedNCT05515406Phase 1
• A Phase 1 Study of ONO-2020 in Healthy ParticipantsCompletedNCT05507515Phase 1
• Safety, Tolerability, PK, PD and Preliminary Efficacy of ONO-4685CompletedNCT05332704Phase 1
• A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)Active, not recruitingNCT05144854Phase 3
• Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)WithdrawnNCT05080621Phase 1/2
• Study of ONO-4685 in Patients With Relapsed or Refractory T Cell LymphomaActive, not recruitingNCT05079282Phase 1
• Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)Active, not recruitingNCT04947319Phase 2
• Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid TumorsTerminatedNCT04892017Phase 1
• A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19)CompletedNCT04657497Phase 3
• A First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of ONO-2808-01 in Healthy ParticipantsCompletedNCT04578028Phase 1
• A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GISTCompletedNCT04530981Phase 1
• Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and PK of ONO-2910 in Japanese and Caucasian SubjectsCompletedNCT04504760Phase 1
• Multiple-dose Study of FOY-305 in Japanese Healthy Adult Male SubjectsCompletedNCT04451083Phase 1
• ONO-7913 Phase I Study (ONO-7913)CompletedNCT04403308Phase 1
• Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GISTApproved for marketingNCT04148092
• Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD of ONO-4685 in Japanese and Caucasian Healthy Adult Male SubjectsCompletedNCT04079062Phase 1
• A Two-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-7684 in Healthy Adult VolunteersCompletedNCT03919890Phase 1
• Single-dose Study to Evaluate the Absolute Bioavailability and Mass Balance of ONO-5788CompletedNCT03849872Phase 1
• Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid TumorsCompletedNCT03730337Phase 1
• A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult VolunteersTerminatedNCT03571594Phase 1
• Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid TumorsTerminatedNCT03182257Phase 1
• Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid TumorsActive, not recruitingNCT03155061Phase 1
• Study of ONO-8577 in Patients With Overactive BladderCompletedNCT03106623Phase 2
• Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell TumorActive, not recruitingNCT03069469Phase 1/2
• Study of Adjuvant ONO-4538 With Resected Gastric CancerCompletedNCT03006705Phase 3
• A Study to Evaluate ONO-4474 in Patients With Pain Due to Osteoarthritis of the KneeTerminatedNCT02997696Phase 2
• Study of ONO-4538 in Gastric CancerCompletedNCT02746796Phase 2/3
• ONO-4538 Study in Patients With Advanced Non-Small Cell Lung CancerCompletedNCT02582125Phase 2
• A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced MalignanciesCompletedNCT02571036Phase 1
• A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacology of ONO-4474 in Healthy VolunteersCompletedNCT02454387Phase 1
• Study of ONO-4538 in Unresectable Advanced or Recurrent Gastric CancerCompletedNCT02267343Phase 3
• ONO-4538 Phase I Study in Patients With Solid TumorCompletedNCT02261298Phase 1

← Ono Pharmaceutical Co. Ltd overview and focus areas